Overview
Bispecific antibodies (BsAbs) and CAR T-cell (CAR T) therapies represent advancements in treatments for blood cancers like diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM). The study assessed demographic and clinical characteristics of patients with DLBCL, FL, and MM who were treated with BsABs and CAR T therapies, and assessed inequities in BsAbs treatment initiation.
Using the Flatiron Health Research Database, researchers analyzed 1,903 patients and identified barriers related to socioeconomic status and neighborhood characteristics that affect access to these advanced therapies. Patients receiving BsAbs were more likely to be older and be treated for MM compared to patients on CAR T. Additionally, patients living in lower socioeconomic status areas and in predominantly Latinx neighborhoods had delayed BsAbs initiation.
Why this matters
The study offers insights into the systemic issues that perpetuate inequities in cancer treatment. Additionally, this research provides a foundation for developing strategies to overcome these challenges, highlighting the need for targeted interventions and policy changes to ensure that all patients, regardless of their background, have access to novel treatments.